Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study

BACKGROUND: Glatiramer acetate (GA) is US-approved for relapsing multiple sclerosis. OBJECTIVES: To describe GA long-term clinical profile. To compare effectiveness of early start (ES) versus delayed start (DS; up to 3 years) with GA. METHODS: Phase 3 trial participants entered a randomized placebo-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ford, Corey C, Cohen, Jeffrey A, Goodman, Andrew D, Lindsey, John W, Lisak, Robert P, Luzzio, Christopher, Pruitt, Amy, Rose, John, Rus, Horea, Wolinsky, Jerry S, Kadosh, Shaul E, Bernstein-Hanlon, Emily, Stark, Yafit, Alexander, Jessica K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442630/
https://www.ncbi.nlm.nih.gov/pubmed/35768939
http://dx.doi.org/10.1177/13524585221094239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442630/
https://www.ncbi.nlm.nih.gov/pubmed/35768939
http://dx.doi.org/10.1177/13524585221094239

Ejemplares similares